Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Stock Short Interest Rises 440.0%

by · The Markets Daily

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 30,190 shares, an increase of 440.0% from the September 30th total of 5,591 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average trading volume of 39,784 shares, the short-interest ratio is presently 0.8 days.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ BGMS traded down $0.01 during midday trading on Tuesday, reaching $0.94. 334 shares of the stock were exchanged, compared to its average volume of 764,851. The company has a 50 day simple moving average of $0.90 and a 200 day simple moving average of $0.98. The stock has a market capitalization of $5.20 million, a P/E ratio of -0.26 and a beta of -0.39. Cyclacel Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.80.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%. The company had revenue of $0.34 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Read Our Latest Research Report on BGMS

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. Its research programs center on small-molecule therapies designed to interfere with key cell-cycle and transcription processes involved in tumor growth.

The company’s pipeline has included fadraciclib (CYC065), an oral cyclin-dependent kinase inhibitor being studied for advanced solid tumors and hematologic malignancies. Cyclacel has also developed sapacitabine (CYC682), an oral nucleoside analog, and seliciclib (CYC202), an earlier-stage cyclin-dependent kinase inhibitor.

Further Reading